Disclosure Statement:
Dr. Izquierdo has nothing to disclose, Dr. C.R. Marion has nothing to
disclose, Dr. Moore reports grants from NIH/NHLBI, grants from
AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline,
Sanofi-Genzyme-Regeneron, and Teva during the conduct of the study;
grants and personal fees from AstraZeneca, and Sanofi Regeneron, grants
from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Gossamer, and
Cumberland Pharmaceuticals outside the submitted work; Karen Raraigh has
nothing to disclose, Dr. Taylor-Cousar: received grants from Vertex
Pharmaceuticals Incorporated, Gilead, N30, Celtaxsys, Proteostasis, and
Bayer; has received fees from Vertex Pharmaceuticals Incorporated
related to consultation on clinical research design, participation on
advisory boards, and speaking engagements; has received speaking fees
from Celtaxsys; and has served on advisory boards and/or provided
consultation for Novartis, Genentech, Gilead, Protalix, Santhera, 4DMT,
AbbVie, and Proteostasis; Dr. Cutting has nothing to disclose; Dr.
Ampleford has nothing to disoclose; Dr. Hawkins has nothing to disclose,
Dr.Zein has nothing to disclose, Dr. Castro receives University Grant
Funding from NIH, American Lung Association, PCORI, Pharmaceutical Grant
Funding from AstraZeneca, Chiesi, Novartis, GSK, Sanofi-Aventis;
consultant fees for Genentech, Theravance, VIDA, Teva, Sanofi-Aventis,
is a speaker for AstraZeneca, Genentech, GSK, Regeneron, Sanofi, &
Teva, and receives Royalties from Elsevier; Dr. Denlinger has grants
from NIH/NHLBI and has consulted with AstraZeneca and Sanofi-Regeneron
during the conduct of the study; the extension of the longitudinal phase
of the SARP cohort has also been supported by AstraZeneca,
Boehringer-Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and
TEVA; Dr. Erzurum reports grants from National Institutes of Health
(NIH), during the conduct of the study; and Chair of the ABIM Pulmonary
Disease Board; Dr. Fahy reports grants from NIH/NHLBI, grants from
Boehringer Ingelheim during the conduct of the study; personal fees from
Boehringer Ingelheim, Pieris, Arrowhead Pharmaceuticals, and Gossamer
outside the submitted work, in addition, Dr. Fahy has a patent
US20110123530A1 - “Compositions and methods for treating and diagnosing
asthma” issued, a patent WO2014153009A2 -Thiosaccharide mucolytic
agents. issued, and a patent WO2017197360 - “CT Mucus Score” - A new
scoring system that quantifies airway mucus impaction using CT lung
scans; Dr. Israel reports personal fees from AstraZeneca, Biometry,
Entrinsic Health Solutions, Equillium, Genentech, GlaxoSmithKline,
Merck, Novartis, 4D Pharma, Pneuma Respiratory, Regeneron
Pharmaceuticals, Sanofi Genzyme, Sienna Biopharmaceutical, TEVA
Specialty Pharmaceuticals, and Vitaeris, Inc; grants from AstraZeneca,
Boehringer Ingelheim, Genentech, GlaxoSmithKline, Merck, Novartis,
Sanofi, TEVA and Vifor-Pharma; non-financial support from Circassia,
Boehringer Ingelheim, Genentech, GlaxoSmithKline, Merck, TEVA Specialty
Pharmaceuticals and Vifor-Pharma; other from Vorso Corp, outside the
submitted work; Dr. Jarjour has grants from NIH/NHLBI and has consulted
with AstraZeneca and Boehringer Ingelheim, and during the extension of
the longitudinal phase of the SARP cohort has also been supported, in
part, by AstraZeneca, Boehringer-Ingelheim, Genentech, GSK,
Sanofi-Genzyme-Regeneron, and TEVA; Dr. Mauger reports grant support
from the NIH, AstraZeneca, Boehringer Ingelheim, Genentech, GSK,
Sanofi-Genzyme-Regeneron, and Teva. L. C. Dr. Levy reports grants from
NIH during the conduct of the study; other from Nocion Therapeutics,
from Entrinsic Health, grants and personal fees from Sanofi, personal
fees from Pieris Pharmaceuticals, Novartis, AstraZeneca, Corbus
Pharmaceuticals, Gossamer Bio, Metera Pharmaceuticals, and Teva, and
grants from Samsung Research America outside the submitted work; Dr.
Wenzel reports grants from NIH and personal fees from AstraZeneca,
grants and personal fees from GSK during the conduct of the study;
grants and personal fees from Sanofi-Regeneron, grants from Boehringer
Ingelheim ,Novartis, and TEVA, and personal fees from Pieris outside the
submitted work; Dr. Woodruff is a consultant for Astra Zeneca,
Theravance, Glenmark pharmaceuticals, Sanofi and Regeneron and has
received funding from Genetech and the COPD Foundation, Dr. Bleecker
reports other from NIH grant, clinical trials through his employer, Wake
Forest School of Medicine and University of Arizona for AstraZeneca,
MedImmune, Boehringer Ingelheim, Genentech, Johnson and Johnson
(Janssen), Novartis, Regeneron, and Sanofi Genzyme, personal fees also
serving as a paid consultant for AztraZeneca, MedImmune, Boehringer
Ingelheim, Glaxo Smith Kline, Novartis, Regeneron, and Sanofi Genzyme
outside the submitted work; Dr. Meyers has nothing to disclose; Dr.
Ortega reports grants from NIH, personal fees from CSL Behring, outside
the submitted work.